The clinical efficiency of BRACAnalysis CDx and HRD tests in predicting platinum based therapy response for breast cancer patients has been announced in a meeting. Additionally, the company is providing an update on key commercial milestones that underscore its commitment to the field of companion diagnostics. "Myriad is committed to advancing the science of companion diagnostics and is currently working with approximately 20 different pharmaceutical companies ...
via Medindia Health News
More READ
No comments:
Post a Comment